Please assess the completion status of the following clinical trial:

Trial Title: Intracoronary Abciximab With Clearway Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients (men or women) at least 18 years of age~2. STEMI: Presenting with ischemic chest discomfort \> 20 minutes and \<6 hours of duration suggestive of acute myocardial infarction AND ST elevation \> 1 mm (\> 0.1 mV) in two contiguous limb leads OR \> 2 mm (\> 0.2 mV) in two contiguous precordial leads~3. Must have signed the informed consent form prior to performance of study-related procedures~4. Native dominant and proximal culprit vessel 2.5 mm in diameter~5. Angiographically identifiable thrombus (presence of a filling defect within the coronary lumen surrounded by contrast medium observed in multiple projections, without calcium within the filling defect, or persistence of contrast medium within the coronary lumen)~6. Pre-PCI Thrombus score (TS) ≥ 2 (angiographically apparent thrombus that is \> ½ the vessel diameter)~7. Pre-PCI TIMI flow grade of 0-2~Exclusion Criteria:~1. Previous PCI of the IRA~2. Previous myocardial infarction or coronary artery bypass grafting~3. Cardiogenic shock~4. Three vessel disease~5. Left main disease~6. Severe valvular heart disease~7. Rescue PCI (PCI following fibrinolytic administration)~8. Facilitated PCI (PCI following fibrinolytic or GP IIb/IIIa inhibition)~9. Contraindication to GP IIb/IIIa inhibitors such as excess bleeding risk or thrombocytopenia~10. Current participation in another investigational trial~11. Exclusion criteria for the MRI imaging include implanted pacemakers, defibrillators, or metallic intracranial implants, severe claustrophobia, BMI \> 35 kg/m², atrial fibrillation or known not well controlled extrasystoles (bad images), or allergy to gadolinium-DTPA~12. Enrolment of patients with an estimated glomerular filtration rate \< 30 ml/min/1.73 m2 should be carefully evaluated considering the gadolinium chelate-associated risk of nephrogenic systemic fibrosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Abciximab (Type: EXPERIMENTAL): IC bolus of abciximab
- IV Abciximab (Type: ACTIVE_COMPARATOR): IV abciximab + infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).